• Entries Atom 1.0
• Comments Atom 1.0
• Entries RSS 2.0
• Comments RSS 2.0
• Podcasts RSS 2.0

• Abbott (10)
• Aids (1)
• Amgen (2)
• asthma (1)
• AstraZeneca (1)
• Avandia (6)
• Baxter (2)
• Bioelectromagnetics (1)
• Bioinformatics (2)
• Biotech Business Models (14)
• Biotechnology (16)
• Boston Scientific (6)
• Bristol Myers Squibb (1)
• Cancer (4)
• Cardiovascular (12)
• Clinical Trials (10)
• CMT (21)
• Diabetes (7)
• Diagnostics (4)
• Drug-eluting stents (9)
• Eli Lilly (2)
• Ethics (5)
• Evidence-Based Medicine (4)
• FDA Reform (17)
• GE Healthcare (5)
• Gene Therapy (1)
• Genomics (2)
• GlaxoSmithKline (5)
• Guidant (4)
• Health impact tax (2)
• Health policy (11)
• Healthcare IT (5)
• Incubators (5)
• Innovation (25)
• Intellectual Property (6)
• InTimeTV (14)
• J and J (7)
• Life Sciences Accelerator (7)
• Medical design (2)
• Medical Diplomacy (2)
• Medical Nanotech (3)
• Medtronic (5)
• Merck (3)
• Midwest (10)
• MIS (5)
• Neurosciences (1)
• Neurosurgery (1)
• Orthopedics (4)
• Partnerships (11)
• Personalized Medicine (10)
• Pfizer (1)
• Pharmaceuticals (18)
• Pharmacogenomics (3)
• Physician Adoption (2)
• Podcast (19)
• Practice of Medicine (17)
• Primary Care (3)
• Private Equity (5)
• Proteomics (1)
• Psychiatry (1)
• RADIOLOGY (2)
• Safety (23)
• Smart Devices (2)
• stem cells (1)
• Stryker (1)
• Surgical Robotics (1)
• Takeda (1)
• Targeted Therapy (1)
• Technology convergence (5)
• Theranostics (5)
• Venture Capital (9)
• Vioxx (4)

• Aesis Research Group, LLC
• DeviceTalk
• BiomaterialsTalk
• MidwestBusiness.com
• Wisconsin Technology Network
• Zangani Investor Community
• Gene Sherpas - Personalized Medicine
• In the Pipeline
• Lab Soft News
• Redington Life Sciences Newsletter
• Venture Beat

The views and opinions on this blog are the personal opinions of the author or its other contributors and commentators. Nothing contained in this blog is intended as medical or investment advice. This blog was created to provide general information, opinions of the author and other contributors and general musings regarding the life sciences, healthcare and their business and investment contexts. This blog is not connected in any way to any company or organization other than the Aesis Research Group, LLC. This blog is not endorsed or supported by any corporation, company, organization, political campaign, political party or special-interest group. This blog/web site is made available by the author and other contributors for educational purposes only and does not endorse any specific company, products, services or securities. Readers are free to make their own interpretations and opinions regarding any specific companies, products, services or public stock. The primary author of this blog cannot be held responsible for any comment to any post on this blog. This is a non-commercial blog.